These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16529965)

  • 1. [What to do with a rising PSA after complete remission post-prostatectomy?].
    Bosset M; Bosset JF; Maingon P
    Cancer Radiother; 2006 Jun; 10(4):168-74. PubMed ID: 16529965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Salvage radiotherapy in rising PSA after radical prostatectomy].
    Carrie C; Pommier P
    Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
    Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
    Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary results of radical surgery and radiotherapy of locally advanced prostate cancer (basal PSA >50 ng/ml)].
    Kaprin AD; Khmelevskiĭ EV; Fadeev AV
    Vopr Onkol; 2007; 53(4):479-81. PubMed ID: 17969415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rising Prostate Specific Antigen following treatment with curative intention].
    Jakobsen H; Pedersen KV
    Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen recurrence after definitive therapy.
    Freedland SJ; Moul JW
    J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant medical treatment or radiotherapy following radical prostatectomy or curative radiotherapy].
    Guy L
    Bull Cancer; 2007 Jul; 94(7 Suppl):F15-20. PubMed ID: 17845989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of persistently detectable PSA after radical prostatectomy.
    Naselli A; Introini C; Andreatta R; Spina B; Truini M; Puppo P
    Int J Urol; 2009 Jan; 16(1):82-6. PubMed ID: 19054168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
    Leonardo C; Simone G; Papalia R; Franco G; Guaglianone S; Gallucci M
    Int J Urol; 2009 Jun; 16(6):584-6. PubMed ID: 19453762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a European perspective.
    Boccon-Gibod L
    BJU Int; 2007 Jan; 99 Suppl 1():2-5; discussion 17-8. PubMed ID: 17229159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.